Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,655 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Whole Blood Clear all
Completed Phase 1 Interventional

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

NCT03396211
View directory record Official record
Conditions
Cancer
Interventions
Apatinib, Nivolumab
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 3 Interventional Results available

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

NCT02366663
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplant, Rituximab
Radiation · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT00765921
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Not applicable Interventional

The Effect of a Scratch Off Prompt on Health Engagement

NCT01401621
View directory record Official record
Conditions
Blood Pressure Check (Hypertension Screening), Cholesterol Test (Lipid Disorder Screening)
Interventions
Scratchoff Prompt: Name of Test, Scratchoff Prompt: Call to Action, Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

NCT01504906
View directory record Official record
Conditions
Healthy
Interventions
cyclosporine, ticagrelor
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 30, 2026, 10:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)

NCT06292104
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
multimodal diagnostic testing
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Not applicable Interventional Results available

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884
View directory record Official record
Conditions
Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cytology specimen collection procedure, therapeutic procedure, targeted therapy, laboratory biomarker analysis
Other · Procedure · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

NCT05083338
View directory record Official record
Conditions
Appendix Carcinoma, Carcinomatosis, Colorectal Carcinoma, Gastric Carcinoma, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Pain Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison Evaluation of Blood Glucose Meter Systems

NCT01548885
View directory record Official record
Conditions
Diabetes
Interventions
CONTOUR® NEXT EZ BGMS, FreeStyle Freedom Lite® BGMS, ACCU-CHEK® Aviva BGMS, TRUEtrack® BGMS, OneTouch® Ultra®2 BGMS
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

NCT00709592
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT, Tacrolimus, Mycophenolate Mofetil
Biological · Radiation · Procedure + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)

NCT00968409
View directory record Official record
Conditions
Breast Cancer
Interventions
PET, Laboratory Testing, Safety Testing, F18-FFNP
Radiation · Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

NCT00496587
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Capecitabine, Gemcitabine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

NCT03420521
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Tumor
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

NCT02690714
View directory record Official record
Conditions
Hypoplasminogenemia, Congenital Plasminogen Deficiency
Interventions
Plasminogen (Human) intravenous
Biological
Lead sponsor
Prometic Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

NCT00472849
View directory record Official record
Conditions
Richter's Transformation, Leukemia
Interventions
Oxaliplatin, Fludarabine, Cytarabine, Rituximab, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)

NCT00175058
View directory record Official record
Conditions
Myocardial Infarction
Interventions
AO Therapy (aqueous oxygen)
Device
Lead sponsor
TherOx
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Zenith TX2® Post-market Approval Study

NCT00813358
View directory record Official record
Conditions
Descending Thoracic Aortic Aneurysm
Interventions
Zenith TX2® TAA Endovascular Graft
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
24
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 30, 2026, 10:24 AM EDT
Not listed Not applicable Interventional

Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI

NCT06000592
View directory record Official record
Conditions
Acute Spinal Cord Injury, Spinal Cord Injuries, Neuromodulation, Traumatic Spinal Cord Injury, Spinal Cord Stimulation, SCI - Spinal Cord Injury, Blood Pressure, Blood Pressure Disorders
Interventions
Digitimer
Device
Lead sponsor
Jill M. Wecht, Ed.D.
Federal
Eligibility
14 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 10:24 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

NCT03341936
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Lirilumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

NCT00399711
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Biomarker of Alzheimer's Disease (AD)

NCT03340571
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

NCT01708564
View directory record Official record
Conditions
Hemophilia
Interventions
rhFVIIa
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Not applicable Interventional Results available

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

NCT02007863
View directory record Official record
Conditions
Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Interventions
Umbilical Cord Blood Transfusion, Fludarabine, Busulfan, Melphalan
Procedure · Drug
Lead sponsor
University of Miami
Other
Eligibility
Up to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 30, 2026, 10:24 AM EDT